ResMed Chief Product Officer Reports 1,848-Share Equity Vesting

Rhea-AI Filing Summary

ResMed Inc. (RMD) filed a Form 4 disclosing that its Chief Product Officer acquired 1,848 shares of common stock on 11/20/2025. These shares came from performance-based restricted stock units that were originally granted on November 16, 2022 and were earned when the compensation and leadership development committee certified that the performance targets were met.

After this transaction, the officer beneficially owns 29,028 shares of ResMed common stock in direct ownership. The transaction was reported as an acquisition at a price of $0, reflecting the vesting of equity compensation rather than an open-market purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leong Justin

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ReMed Common Stock	11/20/2025		A(1)		1,848	A	$0	29,028	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met.

	/s/ Michael J. Rider, attorney-in-fact for Mr. Leong	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ResMed Inc. (RMD) report in this Form 4 filing?

ResMed Inc. reported that its Chief Product Officer acquired 1,848 shares of common stock on 11/20/2025 from the vesting of performance-based restricted stock units.

Who is the reporting person in the ResMed (RMD) Form 4 and what is their role?

The reporting person is a ResMed executive serving as Chief Product Officer, identified in the filing as an Officer of the company.

How many ResMed (RMD) shares does the officer own after this transaction?

Following the reported transaction, the officer beneficially owns 29,028 shares of ResMed Inc. common stock in direct ownership.

What is the origin of the 1,848 ResMed (RMD) shares reported in the Form 4?

The 1,848 shares represent performance-based restricted stock units granted on November 16, 2022, which were earned when performance metrics were certified on November 20, 2025.

Was cash paid for the 1,848 ResMed (RMD) shares acquired in this Form 4?

No cash purchase was reported; the Form 4 lists the price as $0, indicating the shares were acquired through equity compensation vesting.

Does this ResMed (RMD) Form 4 involve derivative securities?

Table II for derivative securities is present but contains no entries, while Table I reports the acquisition of 1,848 shares of common stock from a vested award.